home / stock / bcab / bcab news

BCAB News and Press, BioAtla Inc. From 07/17/25

Stock Information
Company Name: BioAtla Inc.
Stock Symbol: BCAB
Market: NASDAQ
Website: bioatla.com
Menu
BCAB BCAB Quote BCAB Short BCAB News BCAB Articles BCAB Message Board
Get BCAB Alerts

News, Short Squeeze, Breakout and More Instantly...
BCAB - BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company” or “BioAtla”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumo...
BCAB - BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients Dose escalation now continuing at 1.2 mg weekly by subcutaneous flat d...

BCAB - BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen

45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior lines of therapy Marked unmet need exists in 2L+ HPV+ OPSCC patients; standard of care agents (methotrexate, docetaxel, or cetuximab) report an ORR of 3.4% Plan ...

BCAB - BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript

2025-05-06 17:55:40 ET BioAtla, Inc. (BCAB) Q1 2025 Earnings Conference Call May 06, 2025, 04:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Fin...
BCAB - BioAtla GAAP EPS of -$0.26 beats by $0.07

2025-05-06 16:34:06 ET More on BioAtla BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript BioAtla reports Q4 results Seeking Alpha’s Quant Rating on BioAtla Historical earnings data for BioAtla Financial information for BioAtla Rea...

BCAB - BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall...

BCAB - Expected US Company Earnings on Tuesday, May 6th, 2025

Cyclerion Therapeutics Inc. (CYCN) is expected to report for Q1 2025 Standard BioTools Inc. (LAB) is expected to report $-0.06 for Q1 2025 Christian Dior SE ADR (CHDRY) is expected to report for Q1 2025 CF Bankshares Inc. (CFBK) is expected to report for Q1 2025 Jack Henry & A...
BCAB - BioAtla to Participate in the Citizens Life Sciences Conference

SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management...

BCAB - BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference c...

BCAB - BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) , a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentation...
Previous 10 Next 10